Now let me read the remainder of the paper to ensure I have complete coverage of all experimental details and any additional analysis.Now I have thoroughly read the paper. The input "harsh critic" review is essentially empty — just a header with no actual findings. I need to construct a thorough review myself based on my careful reading. Let me draft it.Now let me do calibration. Round 1 — Bracketing:Let me read some of the most relevant anchor papers to calibrate my score.Now let me finalize my review with calibration.

**Round 1 Bracket Analysis:**

The retrieved anchors span:
- **Strong reject range (< 1.5)**: Papers with fundamental issues (hypothetical scenarios, pseudoscience claims) — clearly not our paper
- **Reject range (1.5-3.5)**: MrOefpTvev (2.33) — texture transformer for medical imaging with limited novelty and poor presentation. Our paper is significantly better in both clarity and results.
- **Borderline reject range (3.5-5.5)**: 8g5Ye3c3oR (4.50) — weakly supervised lesion segmentation, rejected for clarity issues. Our paper is clearer but has similar novelty concerns. Also ilGdLPy3mA (3.40) — 3D image block ranking, rejected.
- **Borderline accept range (5.5-7.5)**: NJxCpMt0sf (5.75) — multi-modal MoE for medical imaging, accepted; more general framework with 4 datasets. M3kBtqpys5 (6.25) — multi-view classification, accepted with more novel approach.
- **Accept range (7.5-8.5)**: LeFusion (8.00), ViT registers (8.00) — much stronger novelty and impact.
- **Strong accept range (> 8.5)**: No topically similar papers found.

**Initial bracket: 4.0 – 5.5**

The paper is more polished than rejected papers in the 3-4 range but has less novelty than the accepted papers in the 5.75-6.25 range. Its core contribution is assembling known components (CAM, MoE, cross-attention) for a specific application without validating its central "lesion proposal" claim.

Now let me write the final review.

---

## Summary
This paper proposes an end-to-end framework for multi-view diabetic retinopathy (DR) grading that eliminates the need for external annotations by self-generating lesion proposals. It introduces two modules: GALP (Grade-Activated Lesion Proposal), which uses stage-wise auxiliary classifiers and CAM-derived grade-conditioned evidence maps to select top-K lesion-likely regions, and LGRF (Cross-View Lesion Expert Guided Regional Fusion), which uses MoE-based expert routing and top-K-weighted cross-view attention for selective cross-view fusion. Results on MFIDDR (4-view, 8,613 eyes) and DRTiD (2-view, 3,100 eyes) show competitive or superior performance versus methods requiring external annotations.

## Strengths
- **Competitive performance without external annotations is well-demonstrated.** On DRTiD, the fully end-to-end variant achieves 76.0% accuracy, surpassing all externally informed methods including CrossFiT at 75.6% (Table 3). On MFIDDR, the annotation-free variant (83.9% Acc, 70.9% Kappa) is competitive with externally informed methods like WGLIN (84.2% Acc, 71.2% Kappa) (Table 1). This is the paper's central claim and it is supported.
- **Thorough experimental comparisons.** The paper includes both end-to-end and externally-informed baselines on two datasets, with grade-wise breakdown in Table 2 showing per-class improvements, particularly for clinically important Grade 2 (F1=62.5% w/o lesion, 65.2% with) and Grade 3 (F1=74.1% w/o lesion, 74.8% with).
- **Complete ablation study.** Table 4 shows meaningful drops when removing each component: w/o GALP (−1.2% Acc, −2.4 Kappa), w/o Experts (−1.3% Acc, −2.7 Kappa), w/o LGRF (−1.6% Acc, −3.5 Kappa), confirming complementary contributions.
- **Hyperparameter sensitivity analysis** covers retention ratio α, number of routed experts K₂, and total expert count M (Figure 3), providing practical guidance.

## Weaknesses

### Fatal
None.

### Major
1. **Limited methodological novelty — assembly of known components.** GALP is essentially class activation mapping (CAM, Jiang et al. 2021, cited in the paper) applied at intermediate stages with top-K region selection. LGRF combines standard Mixture-of-Experts routing (Eq. 9–10, following Cao et al. 2023 and Xie et al. 2025, both cited) with cross-attention (Eq. 12–14). Each individual component — CAM for region selection, MoE for dynamic expert routing, cross-attention for multi-view fusion — is well-established. The paper's contribution is their integration for the DR grading task, which reads more as engineering than a methodological advance suitable for a top venue.

2. **"Lesion proposals" are not validated as corresponding to actual lesions.** The paper's core narrative centers on generating "lesion proposals" as surrogates for expert annotations (Abstract: "self-derived cues for grading"; Section 3.2: "regions with higher activation in Ã are more likely to contain lesion evidence"). However, these proposals are CAM-derived grade-conditioned attention regions — spatial areas that are predictive of the grade, which need not correspond to actual clinical lesions. The MFIDDR dataset provides lesion segmentation masks, yet no analysis compares GALP proposals against these ground-truth lesion maps (e.g., IoU, precision/recall). Without this validation, the "lesion proposal" framing is overclaimed.

### Minor
3. **No computational cost analysis.** The method adds substantial overhead: stage-wise auxiliary classifiers at 3 stages, an expert pool of M=6 experts × 3 stages × N views, plus cross-attention modules. No FLOPs, parameter counts, or inference time comparisons are reported, making it difficult to assess practical deployment feasibility — especially given the clinical motivation.

4. **Only cyclic pairwise fusion for cross-view integration.** As described after Eq. 8, cross-view fusion only considers adjacent views in cyclic order (view i with view j = i+1 mod N). For the 4-view MFIDDR setting, view 1 only sees proposals from view 2, never from views 3 or 4. This design choice may miss complementary information from non-adjacent views, and no justification or ablation of alternative fusion topologies is provided.

5. **Single backbone architecture.** All experiments use Swin-B. No evidence is provided that the approach generalizes to other architectures (e.g., ResNet, ConvNeXt), which limits the generality of the contribution.

6. **Ablation and hyperparameter studies only on MFIDDR.** Table 4 and Figure 3 are solely on MFIDDR. No ablation is reported for DRTiD, leaving it unclear whether the component contributions generalize to the two-view setting.

7. **No statistical significance testing.** All results appear to be single runs with no confidence intervals or standard deviations. Given relatively narrow margins (e.g., 83.9% vs. 84.2% Acc on MFIDDR between the proposed method and WGLIN), statistical significance is important to establish.

### Trivial
None.

## Nice-to-Haves
- Qualitative visualization of GALP proposals overlaid on fundus images alongside ground-truth lesion masks from MFIDDR to validate the "lesion proposal" interpretation.
- Computational cost comparison (FLOPs, inference time) with baselines.
- Exploration of all-pairs or full-graph fusion topologies instead of cyclic pairwise.
- Ablation study on DRTiD to confirm component contributions in the two-view setting.
- Results with a second backbone to demonstrate architectural generalizability.

## Removed Points
*These points are flagged to be removed; treat them with caution.*
- The input "harsh critic" review contained no actual weaknesses (only a header "Now let me re-examine a few specific details more carefully"), so there are no reviewer claims to remove.

## Novel Insights
None beyond the paper's own contributions. The idea that CAM-derived attention regions can serve as surrogates for external lesion annotations in a multi-view DR grading pipeline is interesting in principle, but without validation against ground-truth lesions, it remains an unverified hypothesis rather than a demonstrated insight.

## Suggestions
- **Validate GALP proposals against MFIDDR's ground-truth lesion masks** to substantiate the central "lesion proposal" claim. Even a simple IoU or overlap analysis would significantly strengthen the narrative.
- **Report computational costs** (FLOPs, parameters, inference time) to contextualize the added complexity for clinical deployment.
- **Ablate the cyclic fusion topology**: compare cyclic pairwise vs. all-pairs fusion to justify the design choice.
- **Test on additional backbones** to demonstrate the framework's generalizability beyond Swin-B.
- **Add confidence intervals** from multiple runs to establish statistical significance of improvements.

## Score and Decision

**Calibration anchors retrieved:**

| Anchor | Avg Score | Round | Comparison |
|--------|-----------|-------|------------|
| u1cQYxRI1H (IC-Light) | 0.50* | R1 | Irrelevant topic; score data anomaly (listed as Accept with score 10 but retrieved in <1.5 band) |
| nSDOkm0SKo (Financial NN) | 1.00 | R1 | Fundamentally flawed paper; much weaker than ours |
| 5lUdTogEL3 (L-ReID) | 1.00 | R1 | Fundamentally flawed; much weaker |
| gwZ90hFSL2 (Cross-lingual robots) | 1.00 | R1 | Pseudoscience; not comparable |
| MrOefpTvev (Texture Transformer) | 2.33 | R1 | Medical imaging with limited novelty and poor presentation; our paper is significantly better |
| ZZVOrId3yN (CrossModalNet) | 3.00 | R1 | Overclaimed multimodal fusion; our paper has more grounded results |
| ilGdLPy3mA (3D Block Ranking) | 3.40 | R1 | CAM-based medical imaging; weaker novelty and results |
| 1YSJW69CFQ (URF Healthcare) | 1.67 | R1 | Weak method for multi-modal healthcare; much weaker |
| 8g5Ye3c3oR (CoinGAN) | 4.50 | R1 | Weakly supervised lesion segmentation with clarity issues; comparable novelty concerns but our paper is clearer |
| El4Cs8Su3r (LeGrad) | 4.50 | R1 | Explainability for ViTs; rejected for limited novelty — similar issues to our paper |
| Sz2Ar6EqD5 (CrossMR) | 4.00 | R1 | Cross-modality segmentation; rejected |
| Ndq4g76MyH (IMAGE) | 4.00 | R1 | Adaptive masking; rejected for limited contribution |
| NJxCpMt0sf (M4oE) | 5.75 | R1 | Multi-modal MoE for medical imaging; accepted. More general framework, 4 datasets, stronger novelty. Our paper is more application-specific and less novel. |
| M3kBtqpys5 (TEF) | 6.25 | R1 | Multi-view classification with evolutionary search; more novel approach. Our paper lacks similar conceptual novelty. |
| yVJd8lKyVX (HSQ) | 6.00 | R1 | MoE for multi-label; accepted with better novelty framing |
| vqgDq1uycO (MERV) | 6.00 | R1 | Multi-encoder video; rejected despite reasonable contribution |
| 3b9SKkRAKw (LeFusion) | 8.00 | R1 | Strong novelty in lesion synthesis; much more impactful |
| 2dnO3LLiJ1 (ViT Registers) | 8.00 | R1 | Foundational ViT insight; not comparable in impact |

**Round-1 bracket: 4.0–5.5**

**Narrowing rationale:** The paper is clearly above the rejected papers in the 3-4 range (better clarity, stronger results, complete experiments). However, it falls short of the accepted papers at 5.75-6.25, which either have more general frameworks (M4oE), more novel approaches (TEF), or broader evaluation. The main issues pulling it down are: (1) limited novelty — assembly of CAM + MoE + cross-attention, all standard; (2) the unvalidated "lesion proposal" claim that undermines the paper's central narrative; (3) narrow evaluation on only 2 domain-specific datasets with a single backbone. The paper is well-written and shows solid empirical results, which lifts it above a clear reject but not enough for acceptance at a top venue.

**Final score: 4.5**

This is a well-executed application paper with a clear practical motivation and competitive results. However, its contributions are primarily in engineering integration of known components rather than methodological novelty, and its central claim (self-generated lesion proposals) is not validated against ground-truth lesion annotations despite the availability of such data. For ICLR, this places it in the borderline reject territory.

MY FINAL SCORE: <score>4.5</score>
MY FINAL DECISION: <decision>Reject</decision>